Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02105532
Other study ID # 10-09-CSU
Secondary ID ID 12078
Status Completed
Phase Phase 2/Phase 3
First received July 24, 2012
Last updated April 2, 2014
Start date September 2012
Est. completion date August 2013

Study information

Verified date April 2014
Source NHS Blood and Transplant
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

Aim: To evaluate the feasibility and safety of a restrictive versus liberal red blood cell (RBC) transfusion policy in adult patients admitted with Acute Upper Gastrointestinal Bleeding (AUGIB) in order to inform the design of a definitive phase III randomised controlled trial.


Description:

Trial overview: TRIGGER is a pragmatic trial aiming to recruit adult patients admitted with all cause AUGIB (non-variceal and variceal). The study will take place in six United Kingdon hospitals and they will be randomly allocated to a transfusion policy at the cluster level; three sites will be allocated to a restrictive transfusion policy and three to a liberal transfusion policy. Given the challenges that will be involved in early recruitment and cross-speciality care, a feasibility study is essential to determine whether a sufficient proportion of eligible patients can be recruited into the trial and that clinicians can adhere to the allocated transfusion policy. Recruitment will operate for 6 months in total. The investigators will compare recruitment rate, protocol adherence, clinical characteristics of patients recruited, exposure to RBC transfusions and the difference in Hb concentrations between the restrictive and liberal transfusion policies. The investigators will collect important clinical outcomes which the investigators anticipate being central to the phase III trial, including 28-day mortality, further bleeding rates and serious adverse events between the restrictive and liberal transfusion policies. The investigators will also collect data to enable us to plan a health economic evaluation and quality of life assessment for the phase III trial.


Recruitment information / eligibility

Status Completed
Enrollment 936
Est. completion date August 2013
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults aged 18 or over years presenting with AUGIB, defined by haematemesis or melaena.

Exclusion Criteria:

- Patients with whom the responsible clinician considers there is a need for immediate RBC transfusion prior to obtaining or regardless of the initial Hb result due to severity of bleeding.

- Existing hospital in-patients who develop AUGIB.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
Restrictive transfusion policy
Participants allocated to this group will be eligible for transfusion once their Hb level is = 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
Liberal Transfusion Policy
Participants allocated to this group will be eligible for transfusion once their Hb level is = 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.

Locations

Country Name City State
United Kingdom NHSBT Clinical Studies Unit Oxford

Sponsors (2)

Lead Sponsor Collaborator
Dr Vipul Jairath NHS Blood and Transplant

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Red Blood Cell exposure in patients The difference in number of red blood cell units administered will be compared between the intervention groups up to discharge/death/Day 28 (whichever comes first). up to 28 days Yes
Other Selection bias Clinical characteristics of patients in the two transfusion policies 6 months No
Other Difference in Hb concentration Between Restrictive and Liberal Groups The mean Hb values for patients will be compared between the treatment arms up to discharge/death/Day 28 (whichever comes first). up to 28 days No
Other Death All-cause mortality up to Day 28. up to 28 days Yes
Other Need for therapeutic intervention at the index endoscopy This includes any therapeutic modality performed for AUGIB at the index endoscopy. up to 28 days Yes
Other Need for surgery or radiological intervention to control bleeding up to 28 days Yes
Other Proportion of patients experiencing the composite endpoint of thromboembolic and ischaemic events up to Day 28 Includes myocardial infarction, stroke, pulmonary embolus, Deep Vein Thrombosis, acute kidney injury. Each component will also be assessed individually. See section 8.1.3 for a definition of ischaemic and thromboembolic events. up to 28 days Yes
Other Acute Transfusion reactions up to death/ discharge Defined as a reaction occurring at any time up to 24 hours following a transfusion of a blood component. up to 28 days Yes
Other Infections Any infection necessitating a prescription for the use of antibiotic treatment for a minimum of 5 days, provided the prescription is received before or on Day 28. up to 28 days Yes
Other Length of hospital stay up to 28 days Yes
Other Health related quality of life at Day 28 28 days No
Primary Adherence to the study protocol Protocol adherence will be measured over time, to determine if adherence rates improve. Adherence rates will also be compared between transfusion arms. up to 28 days No
Secondary Further Bleeding Further bleeding up to Day 28: Further bleeding is a composite outcome that includes persistent bleeding (defined as any bleeding present at the end of the index endoscopy, regardless of whether endoscopic therapy was attempted or not), and recurrent bleeding. Recurrent bleeding is only assessed in patients without persistent bleeding, and must be confirmed by the presence of high-risk stigmata of bleeding either endoscopically, radiologically, or surgically. Recurrent bleeding should initially be suspected in the event of any combination of the following: fresh haematemesis, continuous melaena, or aspiration of fresh blood from a naso-gastric tube, with a pulse rate of >100 bpm, a fall in systolic blood pressure of >30mm Hg or a drop in Hb of >2g/dL in the preceding 24 hours. Persistent bleeding and recurrent bleeding will also be assessed separately. up to 28 days Yes
See also
  Status Clinical Trial Phase
Completed NCT02903017 - Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage Phase 4
Recruiting NCT02514304 - Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT01477320 - Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients. N/A
Not yet recruiting NCT01549418 - The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Phase 4
Recruiting NCT05226221 - Gastrointestinal Emergency Surgery: Evaluation of Morbidity and Mortality
Active, not recruiting NCT02874326 - Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber Phase 2
Completed NCT02928939 - Therapeutic Conflicts and Multimorbidity
Withdrawn NCT01215058 - Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer N/A
Completed NCT01029626 - Glasgow-Blatschford Score Validation in Digestive Hemorrhage N/A
Completed NCT00251979 - A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer Phase 3
Completed NCT02991612 - Rifaximin in Patients With Gastroesophageal Variceal Bleeding N/A
Recruiting NCT02964195 - Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding N/A
Completed NCT02965209 - European Novel Motorized Spiral Endoscopy Trial N/A
Terminated NCT02609100 - Video Capsule Endoscopy Versus Colonoscopy in Patients With Melena and Negative Upper Endoscopy N/A
Completed NCT01872286 - Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2 N/A
Completed NCT02349490 - Seraseal for Endoscopic Hemostasis Phase 4
Withdrawn NCT01005147 - Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding N/A
Completed NCT00570973 - Band Ligation Versus Transjugular Intrahepatic Portosystemic Stent Shunt (TIPS) in Cirrhotics With Recurrent Variceal Bleeding Non Responding to Medical Therapy Phase 4
Completed NCT00450164 - Secondary Prophylaxis After Variceal Bleeding in Non-Responders Phase 4